RSS-Feed abonnieren
DOI: 10.1055/s-0038-1661049
Stanozolol-Induced Changes in Fibrinolysis and Coagulation in Healthy Adults
Publikationsverlauf
Received 02. September 1983
Accepted 27. Dezember 1983
Publikationsdatum:
19. Juli 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/198402/lookinside/thumbnails/10-1055-s-0038-1661049-1.jpg)
Summary
The effects of orally-administered stanozolol, 5 mg b. d. on fibrinolysis, coagulation and on various haematological and biochemical parameters have been studied in 16 healthy adults, 8 males and 8 females. Statistically significant enhancement of extrinsic (tissue-type) plasminogen activator activity was detected in all subjects studied. This was associated with significant increases in plasma plasminogen and a concomitant reduction in histidine-rich glycoprotein. There were no changes in plasma urokinase activity. Changes in the coagulation system included significant reduction in plasma fibrinogen and elevation of protein C and anti thrombin III. Changes in plasma lipids included significant reduction of HDL cholesterol associated with an increase in LDL triglycerides. No change occurred in total cholesterol. There were no major differences between the sexes, nor were there serious side effects.
The effects of stanozolol on extrinsic (tissue-type) plasminogen activator activity, “free” plasminogen, protein C and antithrombin III, argue strongly in favour of its therapeutic potential.
-
References
- 1 Preston FE, Burakowski BK, Porter NR, Malia RG. The fibrinolytic response to stanozolol in normal subjects. Thromb Res 1981; 22: 543-551
- 2 Davidson JF, Lockhead M, McDonald GA, McNicol GP. Fibrinolytic enhancement by stanozolol: a double-blind trial. Br J Haematol 1972; 22: 543-559
- 3 Cunliffe WJ, Dodman B, Roberts BE, Tebbs EM. Clinical and laboratory double-blind investigation of fibrinolytic therapy in cutaneous vasculitis. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Samama MM, Desnoyers PC. (Eds) Raven Press; New York: 1975. 1 325-332
- 4 Jarrett PE, Morland M, Browse NL. Treatment of Raynaud’s phenomenon by fibrinolytic enhancement. Br Med J 1978; 2: 523-525
- 5 Bumard K, Clemenson G, Morland M, Jarrett PE, Browse NL. Venous lipodermatosclerosis: treatment by fibrinolytic enhancement and elastic compression. Br Med J 1980; 280: 7-11
- 6 Walker ID, Davidson JF. Long-term fibrinolytic enhancement with anabolic steroid therapy: a five year study. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Rowan RM, Samama MM, Desnoyers PC. (Eds) Raven Press; New York: 1978. 3 491-499
- 7 Jarrett PE M, Morland M, Browse NL. Idiopathic recurrent superficial thrombophlebitis: treatment with fibrinolytic enhancement. Br Med J 1977; 1: 933-934
- 8 Fiessinger JN, Aiach M. Stanozolol treatment in an AT III deficient patient. Thromb Haemostas 1980; 43: 183
- 9 Kwaan HC, Robbins KC, Wohl RC. Enhancement of plasma plasminogen level by stanozolol in man. Thromb Haemostas 1981; 46: 114 (Abstr)
- 10 Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol 1981; 68: 181-187
- 11 Agostoni A, Cicardi M, Martignoni GC, Bergamaschini L, Marasini B. Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. J Allergy Clin Immunol 1980; 65: 75-79
- 12 Warm AP, Greaves MW, Gatecliff M, Williamson DM, Warin RP. Treatment of hereditary angioedema by low dose attenuated androgens: disassociation of clinical response from levels of C1-esterase inhibitor and C4. Br J Dermatol 1980; 103: 405-409
- 13 Walker ID, Davidson JF, Young P, Conkie JA. Plasma antithrombin III levels and plasma fibrinolytic activity following oral anabolic steroid therapy. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Samama MM, Desnoyers PC. (Eds) Raven Press; New York: 1975. 1 85-95
- 14 Nieuwenhuizen W, Wijngaards G, Groeneveld E. Fluorogenic peptide amide substrates for the estimation of plasminogen activators and plasmin. Anal Biochem 1977; 83: 143-148
- 15 Vogelaar EF, Brummelhuis AG J, Krijnen HW. Contribution to the optimal use of human blood. III. Large scale preparation of human C1-esterase inhibitor concentrate for clinical use. Vox Sang 1974; 26: 118-127
- 16 Brakman P. Fibrinolysis. A standardized fibrin plate method and a fibrinolytic assay of plasminogen (Thesis) Scheltema & Holkema; Amsterdam: 1967
- 17 Rijken DC, Wijngaards G, Welbergen J. Immunological characterization of plasminogen activator activities in human tissues and body fluids. J Lab Clin Med 1981; 97: 477-486
- 18 Kluft C, Brakman P, Veldhuyzen-Stolk EC. Screening of fibrinolytic activity in plasma euglobulin fractions on the fibrin plate. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Samama MM, Desnoyers PC. (Eds) Raven Press; New York: 1976. 2 57-65
- 19 Buckell M. The effect of citrate on euglobulin methods of estimating fibrinolytic activity. J Clin Pathol 1958; 11: 403-405
- 20 Haverkate F, Brakman P. Fibrin plate assay. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Samama MM, Desnoyers PC. (Eds) Raven Press; New York: 1975. 1 151-159
- 21 Kluft C. C1-inactivator resistant fibrinolytic activity in plasma euglobulin fractions: its relation to vascular activator in blood and its role in euglobulin fibrinolysis. Thromb Res 1978; 13: 135-151
- 22 Kluft C, Jie AF H, Allen RA. Behaviour and quantitation of extrinsic (tissue-type) plasminogen activator in human blood. Thromb Haemostas 1983; 50: 518-523
- 23 Verheijen JH, Mullaart E, Chang GT G, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator, applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
- 24 Wijngaards G, Kluft C, Groeneveld E. Demonstration of urokinase- related fibrinolytic activity in human plasma. Br J Haematol 1982; 51: 165-169
- 25 Kluft C. Studies on the fibrinolytic system in human plasma: quantitative determination of plasminogen activators and proactivators. Thromb Haemostas 1979; 41: 365-383
- 26 Kluft C, Jie AF H. Interaction between the extrinsic and intrinsic systems of fibrinolysis. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Cêpelák V, Samama MM, Desnoyers PC. (Eds) Churchill Livingstone; Edinburgh: 1979. 4 25-31
- 27 Friberger P, Knos M. Plasminogen determination in human plasma. In: Chromogenic peptide substrate. Scully M, Kakkar VV. (Eds) Churchill Livingstone; Edinburgh: 1979: 128-139
- 28 Kluft C, Vellenga E, Brommer E JP, Wijngaards G. A familial haemorrhagic diathesis in a dutch family: an inherited deficiency of α2- antiplasmin. Blood 1982; 59: 1169-1180
- 29 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-53
- 30 Lijnen HR, Hoylaerts M, Collen D. Isolation and characterization of human plasma protein with affinity for lysine binding sites in plasminogen. J Biol Chem 1980; 255: 10214-10222
- 31 Jespersen J, Kluft C. Decreased levels of histidine-rich glycoprotein (HRG) and increased levels of free plasminogen in women on oral contraceptives low in estrogen. Thromb Haemostas 1982; 48: 283-285
- 32 Ellis BC, Stransky A. A quick and accurate method for the determination of fibrinogen in plasma. J Lab Clin Med 1961; 58: 477-501
- 33 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
- 34 Bertina RM, Broekmans AW, Van der Linden IK, Mertens K. Protein C deficiency in a dutch family with thrombotic disease. Thromb Haemostas 1982; 48: 1-5
- 35 Bertina RM, Veltkamp JJ. A genetic variant of factor IX with decreased capacity for Ca2+binding. Br J Haematol 1979; 42: 623-635
- 36 Bertina RM, Orlando M, Tiedemann-Alderkamp GH J. Preparation of a human factor VII deficient plasma. Thromb Res 1978; 13: 537-541
- 37 Kluft C. Determination of prekallikrein in human plasma: optimal conditions for activating prekallikrein. J Lab Clin Med 1978; 91: 83-95
- 38 Dooijewaard G, Kluft C. Contact activation patterns of human plasma measured with a fluorogenic substrate. In: Kinins III: Advances in Experimental Medicine and Biology. Fritz H, Back N, Dietze G, Haberland GL. (Eds) Plenum Press; New York: 1983. 156A 115-120
- 39 Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by simple radial immunodiffusion. Immunochemistry 1965; 2: 235-240
- 40 Laurell CB, Rannevik G. A comparison of plasma protein changes induced by danazol, pregnancy and estrogens. J Clin Endocrinol Metabol 1972; 17: 261-267
- 41 Isacson S, Nilsson IM. Effect of treatment with combined phenformin and ethyloestranol on the coagulation and fibrinolytic systems. Scand J Haematol 1970; 7: 404-408
- 42 Comp PC, Esmon CT. Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest 1981; 68: 122-128
- 43 Meade TW, North WR S, Chakrabarti R, Stirling Y, Yames AP, Thompson SG, Brozovic M. Haemostatic function and cardiovascular death: Early results of a prospective study. Lancet 1980; 1: 1050-1054
- 44 Holland D, Sotto JJ, Berthier R, Leger J, Michallet M. High rate of long term survivals in AML treated by chemotherapy and androgenotherapy. Cancer 1980; 45: 1540-1548
- 45 Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall LM, So AG. Danazol for the treatment of idiopathic thrombocytopaenic purpura. N Engl J Med 1983; 308: 1396-1399
- 46 Miller NE, Hammett F, Saltisse S, Rao S, Van Zeller H, Coltart J, Lewis B. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br Med J 1981; 282: 1741-1744
- 47 Albers JJ, Cheung MC, Hazzard WR. High density lipoproteins in myocardial infarction survivors. Metabolism 1978; 27: 479-485
- 48 Kuusi T, Saarinen P, Nikkila E. Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein2in man. Atherosclerosis 1980; 36: 589-593
- 49 Tikkanen MJ, Nikkila EA, Kuusi T, Sipinen S. Different effects of two progestins on plasma high density lipoproteins (HDL2) and postheparin plasma hepatic lipase activity. Atherosclerosis 1981; 40: 365-369